Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. - Wikidata - awgldk - TriplyDB

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

http://www.wikidata.org/entity/Q43966198

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials Maintenance therapies for multiple myeloma The role of maintenance therapy in multiple myeloma Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy Lenalidomide after stem-cell transplantation for multiple myeloma Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.Bortezomib treatment for multiple myeloma.Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials IMWG consensus on maintenance therapy in multiple myeloma.Evolving treatment strategies for myeloma.Thalidomide: present and future in multiple myeloma.Multiple myeloma: an update of developments in targeted therapy.Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials The adverse prognostic impact of advanced age in multiple myeloma.Cure of multiple myeloma -- more hype, less reality.Maintenance therapy in multiple myeloma.Relevant prognostic features of multiple myeloma and the new International Staging System.The treatment of the elderly multiple myeloma patients.High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.Treatment of relapsed and refractory myeloma.The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma Front line treatment of elderly multiple myeloma in the era of novel agents.Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Guidelines for the diagnosis and management of multiple myeloma 2011.Evolving therapeutic paradigms for multiple myeloma: back to the future.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.

P2860

Q21133524-6B4922FE-F547-4123-B90D-70C34EEAAC65 Q24198800-BCB5789E-2C5D-49B9-96E5-B266DFCFD248 Q28071644-961754E5-56C0-4C93-BE05-F81BE2467EF7 Q28213525-03A1E977-7A76-4E0D-8451-097255F24070 Q34095653-48740D14-6CFF-4CDA-8EDA-77AAE3006E91 Q34122646-089B1B56-642B-4C7D-A5EC-EF98CF0F2663 Q34273726-72BDBCE6-6BC9-4C86-881C-182EDA7EC433 Q34694749-624AA565-31E5-4A8C-9163-2ED5296953F2 Q34973992-F4440AE3-84F3-4CF2-9FBA-4372D1FEDA0B Q35590997-8556E717-E59E-4239-B095-6FAC2B55A265 Q35597062-F073D961-787A-4B1C-BB36-2F800E4A4D96 Q35740019-18B08254-8172-428D-8571-114555B9434D Q35760754-EDF2546F-B675-413F-90C4-FBA8703B5F8D Q35876966-8BFAD924-5159-465B-94A4-486B694F82E4 Q36012354-2D5A9985-6C2B-4331-9C6E-CBE31EFC8DF2 Q36066131-AAB3BFA6-A26A-4225-B56C-D8D90DB573F9 Q36118436-513A1E4B-F6FF-4237-AC08-4AEC7DB562C8 Q36182653-33BFDE30-CA7F-4D4C-BE29-F3558B80C370 Q36194688-EB852250-BD7E-4007-9A5E-DD259AF9C48B Q36301128-D2A08A8A-6CA8-4482-8C8D-040C530A2F66 Q36754178-FBA55FAD-4FEA-45B2-8994-2F534961B360 Q36799829-BEF731BF-CED3-4B27-BC1D-DB8603D2A0A8 Q36799834-498D4196-46D2-4942-B02A-F1358EF916E4 Q36902837-1E2C4279-2C43-4DB9-9F2E-9EF3DB88008C Q36907828-E7B567A3-7B89-4142-8629-76A184E7464F Q37209929-36791988-7CEA-4A05-A144-6EA2FAF36218 Q37209935-DC98319E-874A-49B0-8E61-C7166E936F84 Q37274353-790085C3-2C8D-47DA-BF7A-3C2DDE76A7C8 Q37303213-948CDB1D-B11E-4BA7-8F55-B5CB3A22BB3A Q37373292-C6F20FDD-AB68-4C47-BF67-16E872A822F2 Q37737800-F3A1C7C4-CD1D-49E8-A7BC-9DAEFB332471 Q37761370-7A8917DA-87F4-4E6B-94AD-2476C61FEDF7 Q37875193-D83869BF-A2D2-4374-8A7F-D6013536A993 Q38033590-B16E0729-CB3E-4A42-9C51-373116D32C7D Q38148272-6AF395B2-2C84-48DB-A423-85C2F7AFDDF2 Q38182679-A3046439-86E2-4E76-AC56-023DB868150E Q38191975-9478C577-AACE-445E-AAC0-2A1A61CEA384 Q38231358-78BC1364-E28A-4E7C-9EED-02375553CC5F Q38375463-D312222B-9382-4E7A-A2AF-55FD53FB6F4A Q38375972-EA5365BD-2886-4B70-97A5-05DB3DF889AF

P2860

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

http://www.wikidata.org/entity/Q43966198

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Maintenance therapy with alter ...... in multiple myeloma patients.

@en

Maintenance therapy with alter ...... in multiple myeloma patients.

@nl

type

label

Maintenance therapy with alter ...... in multiple myeloma patients.

@en

Maintenance therapy with alter ...... in multiple myeloma patients.

@nl

prefLabel

Maintenance therapy with alter ...... in multiple myeloma patients.

@en

Maintenance therapy with alter ...... in multiple myeloma patients.

@nl

P1433

Q43966198-0C59C42C-76BB-4D1C-8181-9FA4263A7CCE

P1476

Q43966198-48FAF6F8-1AFC-4341-AFED-4E6FBBB7C3F2

P2093

Q43966198-06398A2B-993C-4F43-9773-FB493CA43D5A

Q43966198-12DB9A66-9435-4B1A-B7CB-D5F5404C92D2

Q43966198-1D0971D4-CAC0-4430-9A3A-93DF01828270

Q43966198-2B19E6C8-3701-4D4B-873B-D3C5F0D41A88

Q43966198-3E531FFD-30BD-4BAB-917B-92BE1E3776E9

Q43966198-45319481-5F17-4EDA-BFD3-8A784E99DC55

Q43966198-58DD0138-C199-477C-A593-36A0E170A72F

P304

Q43966198-77E5866E-C3B4-444D-9C18-DE25AF53CF88

P31

Q43966198-6EAFBD8E-3111-43DF-896B-3F5D18EA7C39

P356

Q43966198-895B6CA2-0953-4DD7-9C46-7E6FBB7AA234

P407

Q43966198-D1D7BF9B-6CD2-459D-9877-365E68948D27

P433

Q43966198-F26E5E97-9B0A-4D3F-B55C-F38F4EDE487C

P478

Q43966198-2DE10CE2-74C2-4C07-BFC2-BBD373101635

P50

Q43966198-40EC464D-0EE7-4111-B5C7-237EE5DE88F8

P577

Q43966198-D6A58EAF-B051-49A1-BCD1-79DA30D7659A

P698

Q43966198-40EB8440-0584-490E-8D9D-2023A7BEC612

P356

BLOOD.V99.9.3163

P1433

P1476

Maintenance therapy with alter ...... in multiple myeloma patients.

@en

P2093

Adrienne D Briggs

http://www.w3.org/2001/XMLSchema#string

Glenn M Mills

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Zangmeister

http://www.w3.org/2001/XMLSchema#string

John J Crowley

http://www.w3.org/2001/XMLSchema#string

Sydney E Salmon

http://www.w3.org/2001/XMLSchema#string

Thomas M Grogan

http://www.w3.org/2001/XMLSchema#string

P304

3163-3168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V99.9.3163

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11964279

http://www.w3.org/2001/XMLSchema#string